- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Catalent Biologics Announces Agreement for SMA Drug Development
Catalent Biologics announced a strategic agreement to develop and manufacture Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal muscular atrophy (SMA).
Through this collaboration, AveXis, a Novartis company, will have dedicated manufacturing space at a new commercial manufacturing center established by Paragon Gene Therapy, a unit of Catalent Biologics. Paragon Gene Therapy will also provide process development for clinical supply of additional viral therapies in the AveXis pipeline.
Fierce Females in the Life Science Space
March 29th 2024In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
